Corcept Therapeutics (CORT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
126.0mn → 120.0mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
−90.3% YoY in FY25 · 0.0% of revenue.
$172.9M returned vs $141.8M of FCF in FY25. The gap comes off the balance sheet (see net cash).
13¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 98.6% → 98.3%. Net margin 13.1% is more than double the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 963,647.0 | 761,407.0 | 675,040.0 | 482,375.0 | 401,858.0 | 365,978.0 | ▲12.8% | +20.1% |
Cost of revenue | 14,097.0 | 12,977.0 | 10,882.0 | 6,481.0 | 5,385.0 | 5,281.0 | ▲19.3% | +25.2% |
Gross profit | 949,550.0 | 748,430.0 | 664,158.0 | 475,894.0 | 396,473.0 | 360,697.0 | ▲12.7% | +20.0% |
Research & development | 241,720.0 | 254,908.0 | 246,887.0 | 184,353.0 | 130,991.0 | 113,864.0 | ▲3.2% | +22.3% |
Selling, general & admin | 596,920.0 | 448,725.0 | 280,320.0 | 184,259.0 | 152,848.0 | 122,356.0 | ▲60.1% | +38.4% |
Total operating expenses | 838,640.0 | 703,633.0 | 527,207.0 | 368,612.0 | 283,839.0 | 236,220.0 | ▲33.5% | +31.4% |
Operating incomefeeds ROC rank | 110,910.0 | 44,797.0 | 136,951.0 | 107,282.0 | 112,634.0 | 124,477.0 | ▼67.3% | −22.5% |
Other income, net | 20,523.0 | 21,666.0 | 24,542.0 | 17,275.0 | 3,557.0 | 529.0 | — | — |
Pretax income | 131,433.0 | 66,463.0 | 161,493.0 | 124,557.0 | 116,191.0 | 125,006.0 | ▼58.8% | −14.6% |
Income tax | −30,859.0 | −33,189.0 | 20,284.0 | 18,417.0 | 14,773.0 | 12,494.0 | — | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 162,292.0 | 99,652.0 | 141,209.0 | 106,140.0 | 101,418.0 | 112,512.0 | ▼29.4% | −3.0% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 1.27 | 0.82 | 1.23 | 0.94 | 0.87 | 0.89 | ▼33.3% | −2.0% |
Diluted shares (mn) | 123.20 | 119.99 | 113.48 | 111.74 | 115.97 | 125.96 | ▲5.7% | −1.2% |
| Margins | ||||||||
Gross margin96th pct in Healthcare | 98.5% | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | ▼0.1pp | −0.3pp |
Operating margin | 11.5% | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | ▼14.4pp | −28.1pp |
Net margin80th pct in Healthcare | 16.8% | 13.1% | 20.9% | 22.0% | 25.2% | 30.7% | ▼7.8pp | −17.7pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Corcept Therapeutics' revenue last fiscal year?
Corcept Therapeutics reported revenue of $761.4M in fiscal 2025, up 12.8% from fiscal 2024.
What was Corcept Therapeutics' net income?
Corcept Therapeutics reported net income of $99.7M in fiscal 2025, a net margin of 13.1%.

